CSI Market
Sign In | Register

Plus Therapeutics Inc (PSTV) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PSTV Annual Cash Flow →
Quarterly cash flow trends provide additional context on Plus Therapeutics Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-15.95
Depreciation & amortization0.23
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventory Write-down0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation1.85
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Warrants-
Change In Fair Value Of Options-
Increase Decrease Other Current Assets-
Increase Decrease Other Assets-
Increase Decrease Deferred Revenue Related Party-
Increase Decrease Of Deferred Revenue-
Joint Venture Acquisition Obligation Accretion-
Gain Loss On Sale Of Product Line Asset-
Extinguishment Of Debt Gain Loss Net Of Tax-
Change In Fair Value Of Warrant Liability-
Provision For Expired Inventory-
Issuance Costs Paid In Common Stock-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Issuance Cost Of Warrants-
Common Stock Issued For Research And Development-
Operating Lease Right Of Use Asset Amortization Expense0.05
Non Cash Financing Expense3.06
Increase Decrease In Grant Receivable-
Increase Decrease In Deferred Grant Liability1.05
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities1.78
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-0.38
Other Noncash Income (Expense)0.00
Other net0.02
Payments for (Proceeds from) Other Operating Activities-0.92
Discontinued operations0.00
Net Cash flow from Operating Activities-13.37
Investing Activities
Capital Expenditures-1.32
Sale of Capital Items0.00
Short-term Investments Proceeds-6.28
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Of Product Line Assets-
Payments For License Agreement Termination Fee-
Cash Acquired In Purchase Of Joint Venture-
Cash Paid For I P R D Asset Acquired In An Asset Acquisition-
Redemption Of Short Term Investments11.31
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net4.43
Discontinued operations0.00
Net Cash Flow from Investing Activities-3.17
Financing Activities
Short-term debt Net-0.77
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-1.36
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net12.28
Proceeds From Exercise Of Employee Stock Options And Warrants-
Finance Lease Principal Payments-
Proceeds From Warrant Exercises-
Proceeds From Issuance Or Sale Of Common And Preferred Stock-
Proceeds From Issuance Of Common Stock Net Of Offering Costs-
Proceeds From Issuance Of Notes Payable And Warrants3.74
Proceeds From Sale Of Common Stock Prefunded Warrants And Warrants15.93
Payment To Investors Pursuant To Letter Agreement-2.29
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.15
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-14.69
Total Cash Flow-6.39
4 historic quarters locked

Sign in to unlock the full Plus Therapeutics Inc cash flow history.

Sign In Create Free Account

About Cerenome Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-352444

Figures are derived from filed reports and may be restated. Historical data is subject to revision.